
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Loading news...

Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

FIGS, QTTB and NESR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 19, 2026.

FIGS, QTTB, ORN, FIX and PIPR have been added to the Zacks Rank #1 (Strong Buy) List on March 19, 2026.

QTTB, DXPE and TTEC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 13th, 2026.

The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

TBLA, MCY, DXPE, CABO and QTTB have been added to the Zacks Rank #1 (Strong Buy) List on March 13th, 2026.

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics to further enable Company's strategic focus on advancing bempikibart for alopecia areata (AA) -- -- Cash and cash equivalents of $48.3 million as of December 31, 2025, combined with gross proceeds from RDO and guaranteed near-term milestone payments from ADX-097 asset sale, expected to provide financial runway into Q4'27 -- WALTHAM, Mass., March 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended December 31, 2025, and provided recent corporate updates.

WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 2:00 p.m.

WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced a $10.5 million registered direct offering.

U.S. stocks traded lower this morning, with the Dow Jones falling around 200 points on Monday.

Q32 Bio Inc. (NASDAQ: QTTB) stock is trading higher on Monday, with a session volume of 70.56 million compared to the average volume of 217.704 thousand as per data from Benzinga Pro.

-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash runway into the second half of 2027 -- -- Eligible to receive up to a total of $592 million including the $12 million in upfront and near-term payments upon achievement of certain development, regulatory and commercial milestones and eligible for tiered royalties up to a mid-teen percent of annual net sales -- -- Q32 Bio retains wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other remaining early-stage assets; continuing to evaluate strategic options for these programs -- WALTHAM, Mass. , Dec. 1, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (NASDAQ: AKBA) ("Akebia").

-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patients in Part A open-label extension (OLE) ongoing -- -- Cash and cash equivalents of $49.0 million as of September 30, 2025 expected to provide financial runway into 2027 -- WALTHAM, Mass. , Nov. 13, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended September 30, 2025, and provided recent corporate updates.

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass. , Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe AA.

WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m.

Q32 Bio (QTTB) Q2 Loss Drops 45%

-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment of Adrien Sipos, M.D., Ph.D., an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, as Interim Chief Medical Officer -- -- Cash and cash equivalents of $54.8 million as of June 30, 2025, which is now expected to provide financial runway into 2027 -- WALTHAM, Mass.

-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass. , June 25, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D.

Squarepoint Ops LLC bought a new position in shares of Q32 Bio Inc. (NASDAQ:QTTB – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,009 shares of the company’s stock, valued at approximately $65,000. Squarepoint Ops LLC owned about 0.16% of Q32 Bio as of its most recent SEC filing. A number of other institutional investors and hedge funds also recently added to or reduced their stakes in QTTB. Rhumbline Advisers grew its holdings in Q32 Bio by 1,164.3% during the fourth quarter. Rhumbline Advisers now owns 105,544 shares of the company’s stock worth $363,000 after acquiring an additional 97,196 shares during the period. Bleakley Financial Group LLC acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $149,000. Raymond James Financial Inc. acquired a new stake in shares of Q32 Bio during the fourth quarter valued at $37,000. Cubist Systematic Strategies LLC purchased a new position in Q32 Bio during the fourth quarter worth about $42,000. Finally, Deutsche Bank AG lifted its position in Q32 Bio by 699.8% during the fourth quarter. Deutsche Bank AG now owns 25,018 shares of the company’s stock worth $86,000 after buying an additional 21,890 shares during the period. Hedge funds and other institutional investors own 31.32% of the company’s stock. Analyst Ratings Changes A number of equities analysts have recently commented on the company. Piper Sandler downgraded Q32 Bio from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $20.00 to $4.00 in a report on Tuesday, February 11th. BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $22.00 to $3.00 in a report on Tuesday, February 11th. Finally, Wells Fargo & Company cut their price objective on Q32 Bio from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Wednesday, March 12th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $24.71. Read Our Latest Report on QTTB Q32 Bio Price Performance Shares of NASDAQ:QTTB opened at $1.68 on Wednesday. Q32 Bio Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $53.79. The business has a 50-day moving average of $1.75 and a two-hundred day moving average of $4.33. The stock has a market capitalization of $20.49 million, a P/E ratio of -0.12 and a beta of -0.03. The company has a debt-to-equity ratio of 0.61, a current ratio of 6.53 and a quick ratio of 6.53. Q32 Bio (NASDAQ:QTTB – Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.33. On average, equities research analysts predict that Q32 Bio Inc. will post -12.32 EPS for the current fiscal year. Q32 Bio Company Profile (Free Report) Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. See Also Five stocks we like better than Q32 Bio Quiet Period Expirations Explained AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway What is a Dividend Harvesting Strategy and How Can Investors Profit from it? Casey’s Surges on Strong Q4, More Gains Likely Ahead What is a Secondary Public Offering? What Investors Need to Know Government Mandate Sends eVTOL Stocks Flying

-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD) granted to bempikibart for the treatment of alopecia areata (AA); SIGNAL-AA Part A results presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Cash and cash equivalents of $65.5 million as of March 31, 2025 expected to provide financial runway into 2H'26 -- WALTHAM, Mass. , May 8, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.